Organon & Co.
A global pharmaceutical company focused on women's health, with products from the contraceptive implant Nexplanon and the fertility drug Follistim AQ to biosimilars like Hadlima, sold across more than a hundred countries. The name comes from the Ancient Greek word for "an instrument for acquiring knowledge," the title of Aristotle's writings on logic. Founded in 1923 in the Netherlands to make insulin, the company was spun off from Merck in 2021, returning to its women's-health roots.
Granted 401.1K · Bought 34.0K
Granted 242.5K · Bought 11.4K
Granted 142.7K
Granted 120.6K
Granted 119.9K · Bought 5.5K
Bought 77.9K
Granted 95.6K · Bought 10.8K
Granted 66.9K · Bought 3.5K
Granted 87.6K
Granted 41.0K
Granted 47.9K
Granted 67.1K
Granted 24.4K
Granted 21.7K · Sold 26.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Ali KevinChief Executive Officer, Director · 21 transactions | +458.5% | 282.7Kas of May 2025 | 401.1K | 34.0K | — |
| Walsh Matthew MChief Financial Officer · 31 transactions | +286.8% | 202.7K | 242.5K | 11.4K | — |
| Morrissey Joseph T. Jr.Interim CEO · 30 transactions | +485.9% | 123.1K | 142.7K | — | — |
| Stahler Rachel AChief Information Officer · 30 transactions | +246.9% | 110.3K | 120.6K | — | — |
| Falcione AaronChief Human Resources Officer · 31 transactions | +513.4% | 96.4K | 119.9K | 5.5K | — |
| Cox Carrie SmithExecutive Chair, Director · 2 transactions | — | 90.3K | — | 77.9K | — |
| Weaver KirkeGen. Counsel & Corp. Secy. · 30 transactions | +587% | 85.6K | 95.6K | 10.8K | — |
| Karp DanielExecutive VP, Corp. Dev. · 15 transactions | — | 71.7K | 66.9K | 3.5K | — |
| Nisita VittorioHead of Global Business Svcs · 30 transactions | +508.9% | 70.6K | 87.6K | — | — |
| Fiedler SusanneChief Commercial Officer · 10 transactions | +102.6% | 54.3Kas of Sep 2024 | 41.0K | — | — |
| DiMarco KathrynCorporate Controller · 18 transactions | +352.1% | 35.9Kas of Mar 2025 | 47.9K | — | — |
| Arjona Ferreira Juan CamiloHead of R&D & CMO · 14 transactions | — | 30.0K | 67.1K | — | — |
| Drinane Juliana PapaInterim Head of Mfg & Supply · 7 transactions | — | 28.8K | 24.4K | — | — |
| Holzbaur LynetteSVP and Corporate Controller · 12 transactions | — | 26.4K | 21.7K | — | 26.4K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +116.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.